- Home
- BDRX vs AZTR Comparison
BDRX vs AZTR Comparison
Compare BDRX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- AZTR
- Stock Information
- Founded
- BDRX 2000
- AZTR 2014
- Country
- BDRX United Kingdom
- AZTR United States
- Employees
- BDRX N/A
- AZTR N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- AZTR Health Care
- Exchange
- BDRX Nasdaq
- AZTR Nasdaq
- Market Cap
- BDRX 3.9M
- AZTR 4.2M
- IPO Year
- BDRX N/A
- AZTR 2023
- Fundamental
- Price
- BDRX $6.80
- AZTR $0.54
- Analyst Decision
- BDRX
- AZTR Strong Buy
- Analyst Count
- BDRX 0
- AZTR 1
- Target Price
- BDRX N/A
- AZTR $4.00
- AVG Volume (30 Days)
- BDRX 350.4K
- AZTR 5.1M
- Earning Date
- BDRX 09-12-2025
- AZTR 11-11-2025
- Dividend Yield
- BDRX N/A
- AZTR N/A
- EPS Growth
- BDRX N/A
- AZTR N/A
- EPS
- BDRX N/A
- AZTR N/A
- Revenue
- BDRX N/A
- AZTR N/A
- Revenue This Year
- BDRX N/A
- AZTR N/A
- Revenue Next Year
- BDRX N/A
- AZTR N/A
- P/E Ratio
- BDRX N/A
- AZTR N/A
- Revenue Growth
- BDRX N/A
- AZTR N/A
- 52 Week Low
- BDRX $5.00
- AZTR $0.50
- 52 Week High
- BDRX $92.00
- AZTR $4.33
- Technical
- Relative Strength Index (RSI)
- BDRX 46.19
- AZTR 34.21
- Support Level
- BDRX $7.21
- AZTR $0.68
- Resistance Level
- BDRX $7.71
- AZTR $1.09
- Average True Range (ATR)
- BDRX 1.00
- AZTR 0.08
- MACD
- BDRX -0.21
- AZTR -0.03
- Stochastic Oscillator
- BDRX 8.47
- AZTR 6.00
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.